PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. - Wikidata - wikimedia - TriplyDB

PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice.

PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice.

http://www.wikidata.org/entity/Q36330881

about

Modulation of mitogen-activated protein kinase-activated protein kinase 3 by hepatitis C virus core protein Hepatitis C virus hijacks host lipid metabolism Mechanisms of intrahepatic triglyceride accumulation Metabolic alterations and hepatitis C: From bench to bedside Contributions of transgenic mouse studies on the research of hepatitis B virus and hepatitis C virus-induced hepatocarcinogenesis Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen HCV and Oxidative Stress: Implications for HCV Life Cycle and HCV-Associated Pathogenesis Metabolic factors and chronic hepatitis C: a complex interplay Mouse models for the study of HCV infection and virus–host interactions Hepatitis C Virus Nonstructural 4B Protein Modulates Sterol Regulatory Element-binding Protein Signaling via the AKT Pathway Molecular mechanisms of insulin resistance in chronic hepatitis C Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress Integrated analysis of mutation data from various sources identifies key genes and signaling pathways in hepatocellular carcinoma.Hepatic inflammation mediated by hepatitis C virus core protein is ameliorated by blocking complement activation.Nutrigenomics therapy of hepatisis C virus induced-hepatosteatosis.Production and pathogenicity of hepatitis C virus core gene products.PPARalpha: energy combustion, hypolipidemia, inflammation and cancer Hepatocarcinogenesis associated with hepatitis B, delta and C viruses.Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.Quinolinate Phosphoribosyltransferase is an Antiviral Host Factor Against Hepatitis C Virus Infection.Enhanced hepatitis C virus genome replication and lipid accumulation mediated by inhibition of AMP-activated protein kinase Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse Role of white adipose lipolysis in the development of NASH induced by methionine- and choline-deficient diet.Viral hepatocarcinogenesis.HCV 3a core protein increases lipid droplet cholesteryl ester content via a mechanism dependent on sphingolipid biosynthesis.The hepatitis C virus core protein inhibits adipose triglyceride lipase (ATGL)-mediated lipid mobilization and enhances the ATGL interaction with comparative gene identification 58 (CGI-58) and lipid droplets Differential regulation of cytotoxicity pathway discriminating between HIV, HCV mono- and co-infection identified by transcriptome profiling of PBMCs.Adipocyte-specific disruption of fat-specific protein 27 causes hepatosteatosis and insulin resistance in high-fat diet-fed mice.Increased incidence of aflatoxin B1-induced liver tumors in hepatitis virus C transgenic mice Oncogenic potential of hepatitis C virus proteins Hepatitis C virus core protein decreases lipid droplet turnover: a mechanism for core-induced steatosis.Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.Hepatitis C virus-induced hepatocellular carcinoma Hepatic Cerebroside Sulfotransferase Is Induced by PPARα Activation in Mice PPARα Activation Protects against Anti-Thy1 Nephritis by Suppressing Glomerular NF-κB Signaling.PPARs in Liver Diseases and Cancer: Epigenetic Regulation by MicroRNAs.Mechanism of the development of nonalcoholic steatohepatitis after pancreaticoduodenectomy.Characterization of bioactive agents in five types of marketed sprouts and comparison of their antihypertensive, antihyperlipidemic, and antidiabetic effects in fructose-loaded SHRs.

P2860

Q24336062-77EAD9B6-7308-41E9-B5EF-89C865A4C573 Q24652319-B7ACD27F-6F6F-41D5-95A9-EB389D52C8D2 Q26773198-13CE47B4-4FCD-4746-BA61-B6BF219DE309 Q26773261-6AD16603-6BC5-4F51-B2A4-9BE16F4DA5EA Q26775804-FC97C3B3-26FB-4099-8982-07FAB76E6E57 Q26779128-031B8C4F-9DFD-434B-97F1-B1B07C7D8053 Q26861095-A9B2FD24-2768-497B-9216-E866C288BF71 Q26996778-42A58A33-CF5C-4002-AD65-A27B1D448681 Q27011787-01DFCCF0-8833-4DEB-8D22-1D0CA6F89685 Q27486807-69CC0CAF-2D35-4044-8CA2-8F693CAEBDF4 Q27488294-8BFA136A-F74F-43AA-928D-F2280EAD7246 Q27489665-BD94C1DD-9B86-4BFB-BC58-A8BD9A343CB1 Q28075646-A56383F4-C54E-46C3-A5E1-89B683C2D02D Q28242949-83BE15F1-10EC-4E48-A637-2C195ED393CF Q30834745-87C79169-5462-416F-B353-6E6D11131AEE Q33491812-0FFD1F45-8614-48EA-8070-EC49B3908AB6 Q33582787-7039F0FE-4E22-4982-908F-F43E3341C93F Q33780095-16A8CB98-E673-4CDA-A5F3-06D7D7312338 Q33805104-A82FB3B8-44F1-43B0-9016-D65B264A517E Q33899640-1141ABE9-BD17-4147-913C-69CD4997FD74 Q33904328-1BCA9FC5-54ED-4202-9A19-419FCB2E66D6 Q33918411-7571E78C-A07B-4DCB-9796-9D962D10FAEA Q33953064-0E8CCBBA-35DF-4D94-87B0-BD5827D10FE5 Q34009002-3C216B12-89F9-4698-9BD2-30E13B98574D Q34302360-DC180C01-0ABB-4E28-87DB-BB113200EFAE Q34617749-D08C3519-2A03-4F89-BFFC-A18CBE4C78D3 Q34734158-89923900-0EF9-47A4-BCF0-1AD64959A23B Q34774442-1377499C-60A1-4690-A4C8-1778B8BA959B Q35033949-8D752A7A-5DC0-4EC0-A263-63AE23FF028C Q35048863-0AF50D85-11DC-40E1-9087-87E6BFC7E97A Q35179492-E6F0F54A-EF06-4668-A72F-28A396AA3F25 Q35261292-40B26F54-DEF2-464D-A54A-45B0D95537BF Q35604983-F715E540-4DE2-4BDB-AA25-E4706F0DD76E Q35619104-15D8E479-97B4-487C-BC23-E5CCF67D45EC Q35824057-DC5DB393-0B3D-4389-A2FA-D29781A313FD Q35975150-A09A7E4F-662F-4ABD-BCD9-0CA623D458C4 Q35997191-01389C8B-6992-45F2-A3B8-2877F3D19D14 Q36253614-D35F4672-B3B9-4AFF-8F67-44C543A4AF2A Q36323842-51BA5C6F-4F15-40A1-A656-C8CA08E03DEF Q36458743-6306C186-82FE-4062-A9E5-0A335EF70364

P2860

PPARalpha activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice.

http://www.wikidata.org/entity/Q36330881

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

PPARalpha activation is essent ...... atocellular carcinoma in mice.

@ast

PPARalpha activation is essent ...... atocellular carcinoma in mice.

@en

type

label

PPARalpha activation is essent ...... atocellular carcinoma in mice.

@ast

PPARalpha activation is essent ...... atocellular carcinoma in mice.

@en

prefLabel

PPARalpha activation is essent ...... atocellular carcinoma in mice.

@ast

PPARalpha activation is essent ...... atocellular carcinoma in mice.

@en

P1433

Q36330881-6F45FDC4-46A7-4135-8057-119559496485

P1476

Q36330881-061F3B58-A1D6-420B-AA03-03E2D98CE493

P2093

Q36330881-447B6622-3F05-4DE5-AEE4-26224B2E75C5

Q36330881-928AC815-C6B0-4560-9100-9CEE901190B6

Q36330881-975AC32D-FF8D-4F59-9B44-26E26DA23B31

Q36330881-ACF5710F-6363-4DCF-86A1-064A51EE590F

Q36330881-EF55B741-EF5D-4226-9D17-D508BBB1AEDF

P2860

Q36330881-036345B4-423F-40E3-AC49-585031AEFD8F

Q36330881-086149CA-7F1C-4D61-BF39-F40B9CA82962

Q36330881-0B63F876-C837-4B73-9719-713BCC10813D

Q36330881-122C14C1-C98F-44D3-BBA8-5A6A65F3A98F

Q36330881-171EBBB9-19EF-4E1E-B575-68EAFFD9ABBF

Q36330881-1A5FB865-D628-4C12-9835-9D9F57058722

Q36330881-1D2D22F4-41E4-4FA1-984B-71FF110262B2

Q36330881-2221CDAF-F5F3-411C-938F-86966A140EDD

Q36330881-22F0824D-62D4-4BC9-9428-C7BC15E1B7B0

Q36330881-2BB47EC4-35FF-4CFA-887D-49DE8981B1D7

P304

Q36330881-404C35D3-4D21-46E2-AD32-D843F1B437A4

P31

Q36330881-A92BF10A-EC2A-4F7E-BF84-5E33DBDF6C69

P356

Q36330881-951C0DBE-E60A-40C0-B8EC-1A4FC543EB89

P407

Q36330881-550F240D-2A30-4030-A451-E1558A67EEF6

P433

Q36330881-E656D763-9622-4812-8C28-07CBEE5DD43D

P478

Q36330881-40E5FA88-386D-4635-8459-D4F11DEFAD9C

P50

Q36330881-F0B28C35-E4CF-4690-9622-0A6D8C4C36C4

P577

Q36330881-84920C39-4161-45BB-8EEC-DCE7D72FDB4C

P698

Q36330881-D4F8BE63-7388-4A1D-A082-B933C36C7A95

P932

Q36330881-F7EEBD0E-BC84-4C26-8A69-6EC21971A32D

P356

P1433

Journal of Clinical Investigation

P1476

PPARalpha activation is essent ...... atocellular carcinoma in mice.

@en

P2093

Frank J Gonzalez

http://www.w3.org/2001/XMLSchema#string

Kendo Kiyosawa

http://www.w3.org/2001/XMLSchema#string

Kyoji Moriya

http://www.w3.org/2001/XMLSchema#string

Naoki Tanaka

http://www.w3.org/2001/XMLSchema#string

Toshifumi Aoyama

http://www.w3.org/2001/XMLSchema#string

P2860

Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity

Hepatitis C virus core protein regulates p300/CBP co-activation function. Possible role in the regulation of NF-AT1 transcriptional activity

Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators

A simple method for the isolation and purification of total lipides from animal tissues

A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades

Critical role of PA28 in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis

Peroxisome proliferator-activated receptor alpha target genes

Mechanism of action of fibrates on lipid and lipoprotein metabolism

Peroxisome proliferator-activated receptors: nuclear control of metabolism

Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha)

P304

683-694

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI33594

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18188449

http://www.w3.org/2001/XMLSchema#string

P932

2176192

http://www.w3.org/2001/XMLSchema#string